NASDAQ
Dianthus Therapeutics, Inc. (DNTH)
♥ 712 Thanks from members
Dianthus Therapeutics (DNTH) exhibits strong positive market sentiment driven by a robust cash runway through 2030, a promising neuromuscular pipeline anchored by claseprubart, and upcoming late-2026 clinical catalysts, though concentration risks and Phase 3 translation hurdles remain key focal points.